New Insight Into FGFR1 Gene's Possible Role in ER+ Breast Cancer Endocrine Resistance

Share this content:
Fibroblast growth factor receptor 1 gene and ligand co-amplification is associated with endocrine resistance in breast cancer cells.
Fibroblast growth factor receptor 1 gene and ligand co-amplification is associated with endocrine resistance in breast cancer cells.

SAN ANTONIO—Fibroblast growth factor receptor 1 (FGFR1) gene and ligand co-amplification is associated with endocrine resistance in estrogen receptor-positive (ER+) breast cancer cells, according to a preclinical in vitro study presented at the 2015 San Antonio Breast Cancer Symposium.1

“FGF3/4/19 and FGFR1 expression are upregulated upon estrogen deprivation, suggesting it is a mechanism of adaptation and/or resistance to endocrine therapy,” reported lead author Luigi Formisano, of Vanderbilt University Medical Center in Nashville, TN. “We hypothesize ER+/FGFR1-amplified tumors should be treated with a combination of antiestrogens and FGFR antagonists.”

FGFR1 interaction with ER in the nucleus “increases upon estrogen deprivation in FGFR1-amplified primary tumors,” he said. “FGFR1 tyrosine kinase activity is required for the interaction of FGFR1 and estrogen receptor. The FGFR1 TKI lucitanib reduces ER transcriptional activity.”

ER+ breast cancers initially respond to antiestrogens but eventually become hormone-independent and recur, Formisano noted. FGFR1 is amplified in approximately 10% of ER+ breast cancers (and up to 27% of luminal B-subtype breast cancers) and amplification is associated with resistance to antiestrogen therapy and poor outcomes among patients with ER+ breast cancer, he noted. It has been hypothesized that FGFR signaling mediates resistance to hormonal therapies through activation of the MAPK and PI3K pathways.

RELATED: Gene Transcription Signatures Predict Survival After Tamoxifen, CAF Chemotherapy

The research team is now investigating genes modulated by ER/FGFR1 in ER+ breast and preclinical “in-vivo antitumor efficacy of dual inhibition of FGFR1 and ER in ER+/FGFR1-amplified patient-derived breast cancer xenografts.”

Reference

  1. Formisano L, Young CD, Bhola NE, et al. Nuclear FGFR1 interaction with estrogen receptor (ER) α is associated with resistance to endocrine therapy in ER+/FGFR1-amplified breast cancer. Oral presentation at: San Antonio Breast Cancer Symposium 2015; December 10, 2015; San Antonio, TX.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs